Bio-Techne Corp (TECH)
62.12
-0.12
(-0.18%)
USD |
NASDAQ |
Apr 19, 16:00
62.12
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 9.766B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -25.86% |
| Valuation | |
| PE Ratio | 45.02 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.759 |
| Price to Book Value | 4.973 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.08 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2276 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 60.51% |
Profile
| Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. |
| URL | https://www.bio-techne.com |
| Investor Relations URL | https://investors.bio-techne.com/ |
| HQ State/Province | Minnesota |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 09, 2024 |
Ratings
Profile
| Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%. |
| URL | https://www.bio-techne.com |
| Investor Relations URL | https://investors.bio-techne.com/ |
| HQ State/Province | Minnesota |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | May. 01, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 09, 2024 |